This peer-reviewed study published in Nutrients provides the first comprehensive characterization of the oral pharmacokinetics, endocrine effects, and metabolic actions of D-Pinitol under fasting conditions. The research demonstrates that D-Pinitol is rapidly absorbed after oral intake, reaches systemic circulation and liver tissue, and is cleared without accumulation, confirming its suitability as a dietary ingredient.
Functionally, D-Pinitol significantly reduces circulating insulin levels while maintaining stable glycemia, resulting in a marked reduction of insulin resistance (HOMA-IR). This insulin-sparing effect is mediated by increased ghrelin secretion and direct inhibition of pancreatic insulin release, combined with adaptive hepatic metabolic regulation. Importantly, no liver or kidney toxicity was observed at the tested doses.
These findings establish D-Pinitol as a pancreatic-protective metabolic modulator that reduces insulin demand without compromising glucose homeostasis, providing a strong scientific foundation for Agelity® in metabolic health, aging, and insulin resistance management.